{"gene":"BMPR2","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2000,"finding":"BMP-2 binds BMPR-II via a low-affinity epitope assembled from determinants of a single monomer (epitope 2), distinct from the high-affinity BMPR-IA binding epitope 1. Mutations in epitope 2 produce BMP-2 antagonists that partially or completely inhibit BMP-2 activity, defining the receptor recognition mechanism.","method":"BMP-2 mutant proteins analyzed for binding to receptor ectodomains; C2C12 cell bioassay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis and functional cell-based validation in a single rigorous study","pmids":["10880444"],"is_preprint":false},{"year":2003,"finding":"Tctex-1, a dynein light chain, interacts with the cytoplasmic domain of BMPR-II and is phosphorylated by BMPR-II. This interaction is isoform-specific (requiring the long cytoplasmic tail encoded partly by exon 12) and is disrupted by PPH disease-causing mutations within exon 12. BMPR-II and Tctex-1 co-localize in pulmonary vascular endothelium and smooth muscle.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro phosphorylation assay, immunofluorescence co-localization","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (Y2H, Co-IP, in vitro kinase assay, co-localization) in single lab","pmids":["14583445"],"is_preprint":false},{"year":2004,"finding":"GST pull-down with BMPR-II cytoplasmic domain constructs identified 33 interacting proteins including PKCβ and CtBP (confirmed by immunodetection), and showed that the C-terminal tail of BMPR-II provides distinct binding sites for regulatory proteins linking BMP signaling to MAP kinase pathway, apoptosis, transcription, PKCβ, and PKA.","method":"GST pull-down assay, 2D gel electrophoresis, MALDI-TOF-MS, immunodetection confirmation","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry interactome with two confirmed interactions by immunodetection, single lab","pmids":["15188402"],"is_preprint":false},{"year":2008,"finding":"PAH-causing BMPR2 nonsense and frameshift mutations trigger nonsense-mediated decay (NMD), establishing haploinsufficiency as the predominant molecular mechanism. Missense mutations cause heterogeneous functional defects including impaired type I receptor phosphorylation and altered receptor complex stoichiometry. The intracellular domain of BMPR-II is both necessary and sufficient for receptor complex interaction.","method":"Enzymatic and fluorescence activity-based assays, splicing analysis, NMD inhibition, cell-based BMPR-II activity assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal functional methods establishing NMD, receptor stoichiometry, and domain sufficiency; consistent with independent studies","pmids":["18321866"],"is_preprint":false},{"year":2009,"finding":"GDF5 and BMP2 prevent apoptosis in mouse embryonic fibroblasts (but not smooth muscle cells) via BMPR2. The mechanism involves BMPR2 stimulating the interaction with XIAP, reducing XIAP ubiquitination and increasing XIAP protein stability, which then inactivates activated caspases. This anti-apoptotic effect does not depend on Smad or MAPK signaling.","method":"Co-immunoprecipitation, ubiquitination assay, BMPR2 loss-of-function, caspase activity assay, cell viability assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and functional rescue experiments, single lab, multiple orthogonal methods","pmids":["19782107"],"is_preprint":false},{"year":2011,"finding":"BMPR2 mutations in pulmonary microvascular endothelial cells activate the Rho GTPase Rac1, causing cytoskeletal defects. Exogenous recombinant ACE2 corrects Rac1 defects in vitro and reverses established PAH in vivo in Rosa26-Bmpr2R899X transgenic mice.","method":"Expression arrays, Rac1 activity assay, stable transfection of BMPR2 mutations, in vivo mouse model with rhACE2 treatment","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell lines and in vivo rescue, single lab","pmids":["22180660"],"is_preprint":false},{"year":2011,"finding":"Mutant BMPR-II expression in pulmonary arterial endothelial cells increases susceptibility to apoptosis and causes secretion of elevated TGF-β1 and FGF2, which stimulate pulmonary arterial smooth muscle cell proliferation. Neutralizing antibodies to TGF-β1 or inhibitors of ALK-5 or FGFR1 blocked this paracrine proliferative effect.","method":"Adenoviral overexpression of wild-type or kinase-deficient BMPR-II mutant in PAECs, conditioned media experiments, ELISA, TGF-β bioassay, neutralizing antibodies, small molecule inhibitors","journal":"Pulmonary circulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional conditioned media and neutralization experiments, single lab, multiple orthogonal approaches","pmids":["22034596"],"is_preprint":false},{"year":2012,"finding":"BMPR-II deficiency promotes activation of SMAD-independent MAPK pathways via TGFβ-associated kinase 1 (TAK1), resulting in pro-proliferative and anti-apoptotic responses in pulmonary arterial smooth muscle cells. TAK1 interacts with BMPR-II and inhibits BMP-responsive reporter activity; this interaction is greatly reduced by PAH-causing BMPR2 mutations.","method":"Primary PASMCs from knock-in mice, TAK1-MAPK inhibition rescue experiments, reporter assay, co-immunoprecipitation, in vivo rat PAH models","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP, reporter assays, epistatic rescue, and in vivo validation across multiple models in single study","pmids":["22388934"],"is_preprint":false},{"year":2012,"finding":"Estrogen receptor alpha directly binds to a conserved site in the BMPR2 promoter (demonstrated by gel-shift/EMSA assay), and increased estrogen receptor alpha expression correlates with decreased BMPR2 transcription. Exogenous estrogen decreases BMPR2 expression in proliferating cells.","method":"Quantitative RT-PCR, gel mobility shift assay (EMSA), luciferase reporter assay, estrogen receptor transfection in cell culture, in vivo mouse studies","journal":"Biology of sex differences","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — EMSA, luciferase, and in vivo data; single lab, multiple orthogonal methods","pmids":["22348410"],"is_preprint":false},{"year":2013,"finding":"FK506 (tacrolimus) activates BMPR2 signaling via a dual mechanism: as a calcineurin inhibitor and by releasing FKBP12 from type I receptors ALK1, ALK2, and ALK3, thereby activating downstream SMAD1/5 and MAPK signaling and ID1 gene regulation. Low-dose FK506 reversed dysfunctional BMPR2 signaling in PAH patient endothelial cells and reversed established PAH in multiple rodent models.","method":"High-throughput luciferase reporter screen, FKBP12 binding assay, SMAD1/5 and MAPK phosphorylation assays, in vivo rat PAH models, conditional Bmpr2 deletion mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic dissection with multiple orthogonal methods, multiple in vivo models, validated in patient-derived cells","pmids":["23867624"],"is_preprint":false},{"year":2013,"finding":"Chloroquine increases cell surface expression of BMPR-II protein by inhibiting lysosomal degradation, independent of transcription. Cell surface BMPR-II has rapid turnover that is blocked by chloroquine. This restores BMP9-induced BMPR-II signaling (Id1, miR21, miR27a expression) in endothelial cells from PAH patients with BMPR-II mutations.","method":"Protein synthesis inhibition, cell surface expression assay, siRNA knockdown, BMP9 signaling assays (Id1, miR21/27a), blood outgrowth endothelial cells from PAH patients","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in patient-derived cells, single lab","pmids":["23669347"],"is_preprint":false},{"year":2013,"finding":"Uterine decidua-specific deletion of Bmpr2 in mice leads to midgestation decidualization defects, abnormal vascular development, trophoblast defects, and deficiency of uterine natural killer cells. Absence of BMPR2 signaling in the uterine decidua suppresses IL-15, VEGF, angiopoietin, and corin signaling, resulting in placental abruption and fetal demise.","method":"Conditional Bmpr2 knockout (uterine-specific Cre), histology, immunofluorescence, gene expression analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with specific molecular pathway and multi-pathway phenotypic readout","pmids":["23676498"],"is_preprint":false},{"year":2014,"finding":"Reduced BMPR2 in pulmonary artery endothelial cells, upon TNF stimulation, leads to prolonged phospho-p38 MAPK activity, increased GADD34-PP1 phosphatase activity, dephosphorylation of eIF2α, and consequent derepression of GM-CSF mRNA translation by disrupting stress granule formation. This mechanism increases GM-CSF production, macrophage recruitment, and exacerbates PAH.","method":"siRNA knockdown, phospho-protein analysis, stress granule assays, GADD34-PP1 activity assay, GM-CSF ELISA, GM-CSF infusion and blockade in mouse models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic pathway dissected with multiple biochemical methods and validated in vivo; single lab with multiple orthogonal approaches","pmids":["24446489"],"is_preprint":false},{"year":2015,"finding":"BMPR2 deficiency in pulmonary arterial endothelial cells impairs mitochondrial biogenesis regulators (p53, PGC1α, NRF2, TFAM), reduces mitochondrial membrane potential and ATP production, induces mitochondrial DNA deletion and apoptosis during reoxygenation. In normoxia, BMPR2 reduction increases glycolysis, induces mitochondrial fission, and promotes a pro-inflammatory state.","method":"EC-specific Bmpr2 deletion mouse model, siRNA knockdown in PAECs, mitochondrial function assays (membrane potential, ATP, mtDNA), gene expression analysis","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in vivo plus siRNA in vitro, multiple orthogonal mitochondrial function assays, recapitulated in patient PAECs","pmids":["25863249"],"is_preprint":false},{"year":2015,"finding":"BMP9 is the preferred ligand for BMPR-II-mediated prevention of apoptosis and enhancement of monolayer integrity in pulmonary arterial endothelial cells, including those from PAH patients with BMPR2 mutations. Administration of BMP9 reversed established PAH in BMPR2 R899X knock-in mice and in monocrotaline and Sugen/hypoxia rat models.","method":"BMPR2 R899X knock-in mouse model generation, apoptosis assays, endothelial monolayer integrity assays, in vivo BMP9 administration in three PAH models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — functional in vitro assays, novel knock-in animal model, replicated across three in vivo PAH models","pmids":["26076038"],"is_preprint":false},{"year":2015,"finding":"Loss of BMPR2 in mouse skeletal progenitor cells selectively impairs activin signaling but has no effect on BMP signaling, resulting in an increased bone formation rate and high bone mass. BMPR2 availability mediates receptor-level competition between BMPs and activins for ACVR2A/ACVR2B.","method":"Conditional Bmpr2 knockout in skeletal progenitors (Bmpr2-cKO mice), bone mass measurement, BMP and activin signaling assays, activin sequestration experiments","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with specific signaling pathway discrimination and genetic rescue experiments","pmids":["25663702"],"is_preprint":false},{"year":2016,"finding":"BMPR2 gene delivery increases Smad1/5/8 signaling and reduces Smad2/3 signaling (switching TGF-β-Smad2/3 to BMPR2-Smad1/5/8), and also increases PI3K signaling and decreases p38-MAPK phosphorylation in vivo. These changes are associated with amelioration of PAH in the monocrotaline rat model.","method":"Adenoviral BMPR2 gene delivery to human pulmonary endothelial cells and in vivo rat PAH model, Western blotting for Smad and non-Smad signaling","journal":"Respirology (Carlton, Vic.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both in vitro and in vivo signaling pathway analysis, single lab","pmids":["26809239"],"is_preprint":false},{"year":2018,"finding":"BMPR2 knockdown in multiple myeloma cells potentiates activin A-, activin B-, BMP6-, BMP7-, and BMP9-induced SMAD1/5/8 signaling through wild-type ALK2. The proposed mechanism is that BMPR2 inhibits ALK2-mediated signaling by preventing ALK2 from oligomerizing with ACVR2A and ACVR2B, which are required for ALK2 activation by activins and several BMPs.","method":"siRNA knockdown of BMPR2, SMAD1/5/8 phosphorylation assays, cell death assays in myeloma and HepG2 cells","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional siRNA knockdown with signaling readouts across two cell types; proposed oligomerization mechanism not directly demonstrated by structural method","pmids":["29739878"],"is_preprint":false},{"year":2019,"finding":"BMPR2 deficiency in endothelial cells does not abolish BMP-SMAD1/5 responses but instead promotes formation of mixed heteromeric receptor complexes (BMPR1/TGFβR1/TGFβR2), enabling enhanced TGFβ-SMAD2/3 and lateral TGFβ-SMAD1/5 signaling. Loss of BMPR2 also causes ectopic fibrillin-1 accumulation with active β1-integrin in ILK mechano-complexes at cell junctions, increasing integrin-dependent contractility and retrieval of active TGFβ from latent fibrillin-bound depots.","method":"BMPR2 siRNA knockdown, SMAD phosphorylation assays, co-immunoprecipitation of receptor complexes, fibrillin-1 immunofluorescence, integrin adhesion/spreading assays, actomyosin contractility assays, patient tissue analysis","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal mechanistic methods including Co-IP of receptor complexes, biochemical signaling, matrix biology, and patient tissue validation","pmids":["31826007"],"is_preprint":false},{"year":2019,"finding":"In SMC-EC contact cocultures, BMPR2 in both cell types is required to produce collagen IV, which activates ILK. ILK directs phospho-JNK to the EC membrane, stabilizing presenilin1 and releasing Notch1 intracellular domain (N1ICD) to promote EC proliferation. N1ICD maintains EC proliferative capacity by increasing mitochondrial mass and inducing PFKFB3, which is required for citrate-dependent H3K27 acetylation at enhancer sites.","method":"Co-culture experiments, EC-SMC Bmpr2 double heterozygous mouse model, carotid injury model, ChIP-seq, FRET imaging, conditional Notch1 deletion mice","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple genetic models, ChIP-seq, functional rescue, and FRET imaging in a single comprehensive study","pmids":["30582451"],"is_preprint":false},{"year":2019,"finding":"TWIST1-dependent degradation of GATA-6 in smooth muscle cells reduces BMPR2 expression; GATA-6 directly binds to the BMPR2 promoter and promotes its expression. SMC-specific TWIST1 deficiency or silencing restored GATA-6-dependent BMPR2 expression and attenuated PH development.","method":"SMC-specific TWIST1 knockout mice, TWIST1 silencing in rats, chromatin immunoprecipitation (ChIP), immunoprecipitation (mass spectrometry), Western blotting","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP demonstrated direct GATA-6 binding to BMPR2 promoter; multiple genetic models; single lab with orthogonal methods","pmids":["32692930"],"is_preprint":false},{"year":2019,"finding":"BMPR2 knockout in adipocytes impairs TNFα-stimulated lipolysis by inhibiting perilipin phosphorylation, leading to failure of fatty acid oxidation and oxidative phosphorylation, and consequent mitochondria-mediated apoptosis and pyroptosis with elevated inflammation.","method":"Conditional BMPR2 knockout in adipocytes, lipolysis assays, perilipin phosphorylation assay, fatty acid oxidation assay, apoptosis/pyroptosis assays","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific mechanistic readouts, single lab","pmids":["32350411"],"is_preprint":false},{"year":2019,"finding":"A PINCH-1–Smurf1–BMPR2 signaling axis links extracellular matrix stiffness to mesenchymal stem cell osteogenic differentiation. PINCH-1 interacts with Smurf1, preventing Smurf1 from ubiquitinating and degrading BMPR2. ECM stiffening increases PINCH-1 levels, thereby protecting BMPR2 from degradation and augmenting BMP signaling. Depletion of either Smurf1 or BMPR2 blocks PINCH-1-induced osteogenic differentiation.","method":"Co-immunoprecipitation, ubiquitination assay, PINCH-1/Smurf1/BMPR2 knockdown and overexpression, soft/stiff ECM culture, osteogenic differentiation assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP, ubiquitination assay, epistatic rescue across multiple perturbations, and ECM stiffness experiments in single study","pmids":["31578224"],"is_preprint":false},{"year":2021,"finding":"The kinase domain of the type I receptor ALK2 and the type II receptor BMPR2 form a heterodimeric complex via their C-terminal lobes. This heterodimer serves as the scaffold for assembly of active tetrameric receptor complexes enabling phosphorylation of the GS domain and activation of SMADs. PAH-causing mutations in BMPR2 target this kinase domain heterodimer interface.","method":"Hydrogen deuterium exchange mass spectrometry (HDX-MS), small angle X-ray scattering (SAXS), molecular dynamics (MD) simulations, SMAD signaling assays with PAH-associated mutants","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural study (HDX-MS, SAXS, MD) combined with functional signaling validation and disease mutation analysis","pmids":["34400635"],"is_preprint":false},{"year":2021,"finding":"BMPR2 signaling through SMAD4/SMAD6 maintains high YY1 levels in latently HCMV-infected undifferentiated myeloid cells. BMPR2-activated SMAD4/6 inhibits TGFβ receptor signaling, preventing induction of hsa-miR-29a that would degrade YY1. Pharmacological targeting of BMPR2 in progenitor cells results in YY1 degradation and loss of HCMV latency.","method":"iPSC model of HCMV latency, patient-derived myeloid progenitors, BMPR2 pharmacological inhibition, SMAD4/6 pathway analysis, miR-29a measurement, YY1 protein assays, T cell killing assays","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pharmacological and pathway assays in patient-derived cells and iPSC model; single lab","pmids":["34061599"],"is_preprint":false},{"year":2021,"finding":"BMPR-2 in developing mitral cell dendrites inhibits LIMK activity in the absence of ligands, permitting dendrite destabilization. Ligand-bound BMPR-2 releases LIMK inhibition to stabilize dendrites. LIMK activated by NMDARs via Rac1 facilitates selective dendrite stabilization through F-actin formation.","method":"CRISPR-Cas9-based knockout screening, in utero electroporation, rescue experiments with Bmpr2 re-expression, BMP antagonist/agonist overexpression, Rac1 genetic experiments, FRET imaging of LIMK activity","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR KO with rescue, FRET imaging, and genetic epistasis across multiple neuronal experiments in single study","pmids":["34161760"],"is_preprint":false},{"year":2022,"finding":"SMOC1 binds directly to BMPR-II (via amino acids 372–383 of its EF-hand calcium-binding domain, shown by co-immunoprecipitation) and inhibits BMP2-induced phosphorylation of p38 (p-p38). Under high calcium conditions, SMOC1 loses its ability to bind BMPR-II, promoting p-p38 and cell apoptosis.","method":"Co-immunoprecipitation, domain-mapping with truncation mutants, p38 phosphorylation assays, p38 inhibitor experiments, in vitro and in vivo calcification models","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and functional signaling rescue; single lab","pmids":["33757126"],"is_preprint":false},{"year":2023,"finding":"Loss of BMPR2 in smooth muscle cells causes upregulation of pERK1/2-pP38-pSMAD2/3, elevation of β-arrestin2 (ARRB2), pAKT inactivation of GSK3-beta, CTNNB1 nuclear translocation, and reduction in RHOA and RAC1, resulting in hypocontractile and hyperproliferative PASMC phenotype. Decreasing ARRB2 in BMPR2-deficient SMC restores normal signaling and reverses the aberrant phenotype.","method":"SMC-specific Bmpr2 knockout mice, siRNA in human PASMC, PASMC from PAH patients with BMPR2 mutations, phosphoprotein analysis, ARRB2 knockdown rescue experiments, echocardiography and hemodynamic measurements","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (mouse KO, human siRNA, patient cells), epistatic rescue via ARRB2 knockdown, multiple orthogonal signaling readouts","pmids":["36744494"],"is_preprint":false}],"current_model":"BMPR2 is a type II serine/threonine kinase receptor that forms heterotetrameric complexes with type I receptors (ALK1/2/3) via C-terminal lobe kinase domain dimerization to phosphorylate the GS domain and activate canonical SMAD1/5/8 signaling; it acts as a gatekeeper preventing TGFβ-SMAD2/3 and lateral signaling by competing for type I/II receptor complex formation, regulates non-canonical pathways including MAPK (via TAK1 and ERK/Raf), PI3K, and ARRB2/β-catenin; it phosphorylates dynein light chain Tctex-1, interacts with XIAP to suppress apoptosis, and its cytoplasmic tail recruits PKCβ, CtBP, and other regulatory proteins; its cell-surface abundance is controlled by lysosomal degradation (regulated by PINCH-1/Smurf1 ubiquitination and blocked by chloroquine), and its transcription is suppressed by direct estrogen receptor alpha binding to the BMPR2 promoter and promoted by GATA-6; haploinsufficiency resulting from loss-of-function mutations is the predominant molecular mechanism underlying pulmonary arterial hypertension."},"narrative":{"mechanistic_narrative":"BMPR2 is a type II receptor kinase that nucleates BMP signaling by forming a heterodimeric complex with type I receptor kinase domains (e.g. ALK2) through their C-terminal lobes, a scaffold required for GS-domain phosphorylation and activation of canonical SMAD1/5/8 signaling [PMID:34400635]. Ligand recognition occurs through a distinct low-affinity epitope on BMP ligands separate from the type I receptor epitope [PMID:10880444], and the intracellular domain is necessary and sufficient for receptor complex assembly [PMID:18321866]. Beyond its canonical role, BMPR2 acts as a gatekeeper of receptor pairing: its loss does not abolish SMAD1/5 responses but instead drives formation of mixed BMPR1/TGFβR complexes that potentiate TGFβ-SMAD2/3 and lateral SMAD1/5 signaling [PMID:31826007], and by sequestering shared type II receptors ACVR2A/ACVR2B it restrains activin- and BMP-driven ALK2 signaling [PMID:25663702, PMID:29739878]. The long cytoplasmic tail serves as a regulatory platform, binding and phosphorylating the dynein light chain Tctex-1 in an isoform-specific manner disrupted by disease mutations [PMID:14583445] and recruiting additional partners including PKCβ and CtBP [PMID:15188402]. BMPR2 restrains non-canonical signaling — TAK1-dependent MAPK, p38, ERK, PI3K, and ARRB2/β-catenin axes — such that its deficiency produces pro-proliferative, hypocontractile, and pro-inflammatory states in vascular cells [PMID:22388934, PMID:26809239, PMID:36744494], and it suppresses apoptosis through stabilization of XIAP independently of SMAD/MAPK [PMID:19782107]. Cell-surface abundance is set post-translationally by lysosomal turnover that is opposed by a PINCH-1–Smurf1 ubiquitination axis [PMID:23669347, PMID:31578224], while transcription is repressed by estrogen receptor alpha binding to the BMPR2 promoter [PMID:22348410] and promoted by GATA-6, whose TWIST1-driven degradation lowers BMPR2 [PMID:32692930]. Loss-of-function BMPR2 mutations cause haploinsufficiency, predominantly via nonsense-mediated decay, and are the major molecular cause of pulmonary arterial hypertension [PMID:18321866]; BMPR2 deficiency in pulmonary vascular cells drives endothelial apoptosis, paracrine smooth-muscle proliferation, mitochondrial dysfunction, and inflammatory amplification underlying the disease [PMID:22034596, PMID:25863249, PMID:24446489]. BMPR2 additionally functions across diverse tissues, controlling uterine decidualization and placentation [PMID:23676498], skeletal bone mass via activin signaling competition [PMID:25663702], adipocyte lipolysis [PMID:32350411], and dendrite stabilization in neurons through ligand-gated control of LIMK [PMID:34161760].","teleology":[{"year":2000,"claim":"Established how BMP ligands are recognized by BMPR-II versus the type I receptor, defining the molecular basis of receptor engagement.","evidence":"BMP-2 mutagenesis and binding to receptor ectodomains with C2C12 bioassay","pmids":["10880444"],"confidence":"High","gaps":["Did not resolve the assembled tetrameric receptor architecture","Affinity contributions of full-length membrane receptors not addressed"]},{"year":2003,"claim":"Identified the long cytoplasmic tail as a functional signaling platform by showing isoform-specific binding and phosphorylation of the dynein light chain Tctex-1, linking BMPR-II to disease mutations in exon 12.","evidence":"Yeast two-hybrid, Co-IP, in vitro kinase assay, immunofluorescence","pmids":["14583445"],"confidence":"High","gaps":["Functional consequence of Tctex-1 phosphorylation undefined","Role in dynein-dependent transport not established"]},{"year":2004,"claim":"Mapped the cytoplasmic tail interactome, linking BMPR-II to MAPK, apoptosis, transcription, and kinase pathways through distinct binding sites.","evidence":"GST pull-down, 2D gel, MALDI-TOF-MS, immunodetection","pmids":["15188402"],"confidence":"Medium","gaps":["Only PKCβ and CtBP confirmed; remaining 31 interactions unvalidated","No functional assignment to individual interactions"]},{"year":2008,"claim":"Resolved the molecular mechanism of PAH-causing mutations, establishing nonsense-mediated decay-driven haploinsufficiency and demonstrating the intracellular domain is necessary and sufficient for complex formation.","evidence":"Splicing/NMD analysis and cell-based BMPR-II activity assays","pmids":["18321866"],"confidence":"High","gaps":["Heterogeneous missense defects not mechanistically unified","Downstream pathway consequences of haploinsufficiency not addressed here"]},{"year":2009,"claim":"Defined a SMAD/MAPK-independent anti-apoptotic function of BMPR2 via XIAP stabilization, expanding its role beyond transcriptional signaling.","evidence":"Co-IP, ubiquitination assay, caspase and viability assays in MEFs","pmids":["19782107"],"confidence":"Medium","gaps":["Cell-type specificity (absent in SMCs) unexplained","Mechanism of XIAP de-ubiquitination not identified"]},{"year":2011,"claim":"Connected BMPR2 mutation to vascular cytoskeletal defects via Rac1 activation and identified ACE2 as a corrective intervention in vivo.","evidence":"Rac1 activity assays, mutant transfection, rhACE2 in transgenic mice","pmids":["22180660"],"confidence":"Medium","gaps":["Mechanism linking BMPR2 to Rac1 not defined","How ACE2 corrects Rac1 unclear"]},{"year":2011,"claim":"Showed mutant BMPR-II drives paracrine smooth-muscle proliferation through endothelial secretion of TGF-β1 and FGF2, a non-cell-autonomous disease mechanism.","evidence":"Adenoviral mutant expression, conditioned media, neutralizing antibodies and inhibitors","pmids":["22034596"],"confidence":"Medium","gaps":["Upstream control of cytokine secretion not defined","In vivo relevance of paracrine loop not tested here"]},{"year":2012,"claim":"Identified TAK1 as the mediator coupling BMPR-II deficiency to SMAD-independent MAPK-driven proliferation and survival, with the interaction lost in disease mutants.","evidence":"Primary PASMCs, Co-IP, reporter assays, inhibitor rescue, in vivo rat models","pmids":["22388934"],"confidence":"High","gaps":["Structural basis of TAK1-BMPR-II interaction unknown","Relative contribution versus other non-canonical pathways unquantified"]},{"year":2012,"claim":"Established direct transcriptional repression of BMPR2 by estrogen receptor alpha, providing a basis for sex differences in BMPR2 expression.","evidence":"EMSA, luciferase reporter, ERα transfection, in vivo mouse studies","pmids":["22348410"],"confidence":"Medium","gaps":["In vivo physiological impact on disease not fully resolved","Interaction with other promoter regulators unaddressed"]},{"year":2013,"claim":"Demonstrated pharmacological activation of BMPR2 signaling: FK506 via FKBP12 release and chloroquine via blocked lysosomal degradation, restoring signaling in patient cells.","evidence":"Reporter screen, FKBP12 binding, SMAD/MAPK phospho-assays, in vivo models, patient endothelial cells","pmids":["23867624","23669347"],"confidence":"High","gaps":["Identity of the lysosomal targeting/turnover machinery incompletely defined","Off-target/calcineurin-independent contributions of FK506 not separated in all contexts"]},{"year":2013,"claim":"Revealed an essential developmental role for BMPR2 in uterine decidualization and placentation through control of IL-15, VEGF, angiopoietin, and corin signaling.","evidence":"Uterine-specific conditional knockout, histology, gene expression","pmids":["23676498"],"confidence":"High","gaps":["Direct versus indirect regulation of each downstream factor unresolved","Relevant cell type within decidua not fully defined"]},{"year":2014,"claim":"Dissected an inflammatory amplification mechanism whereby reduced BMPR2 prolongs p38 activity and derepresses GM-CSF translation via GADD34-PP1 and stress-granule disruption.","evidence":"siRNA, phospho-protein and stress-granule assays, GM-CSF ELISA, mouse infusion/blockade","pmids":["24446489"],"confidence":"High","gaps":["How BMPR2 loss sustains p38 activity mechanistically unclear","Generalizability beyond TNF stimulation untested"]},{"year":2015,"claim":"Established BMPR2 as a regulator of endothelial mitochondrial biogenesis, metabolism, and survival, linking its loss to glycolytic shift and apoptosis.","evidence":"EC-specific Bmpr2 deletion, siRNA, mitochondrial function assays, patient PAECs","pmids":["25863249"],"confidence":"High","gaps":["Signaling route from receptor to biogenesis regulators not mapped","Reversibility of metabolic defects untested"]},{"year":2015,"claim":"Identified BMP9 as the preferred protective ligand for endothelial integrity and showed BMP9 reverses established PAH across multiple models, defining a therapeutic ligand axis.","evidence":"R899X knock-in mice, apoptosis/monolayer assays, BMP9 in three PAH models","pmids":["26076038"],"confidence":"High","gaps":["Receptor complex specificity for BMP9 protection not fully resolved","Durability of BMP9 effect untested"]},{"year":2015,"claim":"Revealed BMPR2 sets ligand competition at the receptor level, sequestering type II receptors so that its loss selectively augments activin signaling and bone mass.","evidence":"Skeletal progenitor conditional knockout, BMP/activin signaling and sequestration assays","pmids":["25663702"],"confidence":"High","gaps":["Stoichiometric basis of receptor competition not structurally defined","Tissue-specific differences in competition outcome unexplained"]},{"year":2018,"claim":"Generalized the gatekeeper model, showing BMPR2 loss potentiates ALK2 signaling by permitting ACVR2A/ACVR2B oligomerization with ALK2 in myeloma cells.","evidence":"siRNA knockdown, SMAD1/5/8 phospho-assays in myeloma and HepG2 cells","pmids":["29739878"],"confidence":"Medium","gaps":["Proposed oligomerization mechanism not directly shown by structural method","Single knockdown approach without reciprocal validation"]},{"year":2019,"claim":"Demonstrated that BMPR2 loss reroutes receptor pairing into mixed BMPR1/TGFβR complexes and triggers fibrillin-1/integrin mechano-complex changes that retrieve active TGFβ, mechanistically unifying canonical and matrix-driven dysregulation.","evidence":"siRNA, receptor complex Co-IP, fibrillin-1 IF, integrin/contractility assays, patient tissue","pmids":["31826007"],"confidence":"High","gaps":["Order of events between receptor mispairing and matrix changes unresolved","Quantitative balance of lateral versus canonical signaling unclear"]},{"year":2019,"claim":"Linked BMPR2 in EC-SMC contact to a collagen IV–ILK–JNK–Notch1 axis that maintains EC proliferative metabolism via PFKFB3 and histone acetylation.","evidence":"Co-culture, double-heterozygous mouse model, ChIP-seq, FRET, Notch1 deletion","pmids":["30582451"],"confidence":"High","gaps":["Direct receptor-level trigger for collagen IV production not defined","Whether this axis operates in human disease tissue untested here"]},{"year":2019,"claim":"Established the PINCH-1–Smurf1 axis controlling BMPR2 protein stability and linked ECM stiffness to BMP signaling output in stem cell differentiation.","evidence":"Co-IP, ubiquitination assay, epistatic knockdown/overexpression, ECM stiffness culture","pmids":["31578224"],"confidence":"High","gaps":["How ECM stiffness raises PINCH-1 levels not defined","Relevance to vascular BMPR2 turnover not tested"]},{"year":2019,"claim":"Defined a TWIST1–GATA-6 transcriptional circuit controlling BMPR2 expression, identifying GATA-6 as a direct positive promoter regulator counteracted by TWIST1-driven degradation.","evidence":"SMC-specific TWIST1 knockout, ChIP, IP-MS, in vivo PH models","pmids":["32692930"],"confidence":"High","gaps":["Upstream signals controlling TWIST1 in SMCs unclear","Interaction with ERα-mediated repression not integrated"]},{"year":2019,"claim":"Extended BMPR2 function to adipocyte metabolism, showing it is required for TNFα-stimulated lipolysis, fatty acid oxidation, and protection from mitochondria-mediated cell death.","evidence":"Adipocyte conditional knockout, lipolysis, perilipin phosphorylation, FAO assays","pmids":["32350411"],"confidence":"Medium","gaps":["Direct signaling route from BMPR2 to perilipin phosphorylation unknown","Systemic metabolic consequences not detailed"]},{"year":2021,"claim":"Resolved the structural basis of receptor activation, showing the ALK2-BMPR2 kinase domains form a C-terminal-lobe heterodimer that scaffolds the active tetramer and is targeted by PAH mutations.","evidence":"HDX-MS, SAXS, MD simulations, SMAD signaling with disease mutants","pmids":["34400635"],"confidence":"High","gaps":["High-resolution crystal/cryo-EM structure of full tetramer not obtained","Generality across all type I receptors not tested"]},{"year":2021,"claim":"Uncovered a BMPR2-SMAD4/6-YY1 axis maintaining HCMV latency in myeloid progenitors, identifying BMPR2 as a target for latency reversal.","evidence":"iPSC and patient myeloid latency models, BMPR2 inhibition, miR-29a/YY1 assays","pmids":["34061599"],"confidence":"Medium","gaps":["Direct versus indirect SMAD4/6 control of YY1 not fully separated","Pharmacological specificity of BMPR2 inhibition uncertain"]},{"year":2021,"claim":"Demonstrated a ligand-gated function of BMPR-2 in neurons, controlling dendrite stabilization through inhibition or release of LIMK activity.","evidence":"CRISPR KO screen, in utero electroporation, rescue, FRET imaging, Rac1 epistasis","pmids":["34161760"],"confidence":"High","gaps":["Biochemical mechanism of LIMK inhibition by apo-BMPR-2 undefined","Whether disease mutations affect this neuronal function untested"]},{"year":2022,"claim":"Identified SMOC1 as a calcium-sensitive direct BMPR-II binder that restrains p38 signaling and apoptosis, adding a ligand-independent modulator.","evidence":"Co-IP, domain mapping, p38 phospho-assays, calcification models","pmids":["33757126"],"confidence":"Medium","gaps":["Reciprocal validation of SMOC1-BMPR-II binding limited","Physiological context beyond calcification unclear"]},{"year":2023,"claim":"Defined the integrated non-canonical signaling derangement of BMPR2-deficient smooth muscle and identified ARRB2 as a tractable node whose reduction restores the contractile phenotype.","evidence":"SMC-specific knockout, human/patient PASMC siRNA, phosphoprotein analysis, ARRB2 rescue, hemodynamics","pmids":["36744494"],"confidence":"High","gaps":["How BMPR2 loss elevates ARRB2 mechanistically unknown","Integration with TAK1/p38 pathways not unified"]},{"year":null,"claim":"How the diverse cytoplasmic-tail partners, receptor-competition gatekeeping, and tissue-specific phenotypes are mechanistically integrated into a single quantitative model of BMPR2 signaling output remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking canonical SMAD output to the many non-canonical and matrix-driven effects","Tissue specificity of partner usage undefined","Structural model of the full ligand-bound tetramer incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,3,23]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,23,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[15,17,18]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,7,23,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,6,13]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,13,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,15,25]}],"complexes":["BMP type I/II receptor heterotetramer (ALK2-BMPR2)","PINCH-1-Smurf1-BMPR2 axis","ILK mechano-complex (matrix-associated)"],"partners":["ALK2","TAK1","XIAP","TCTEX-1","PKCB","CTBP","SMOC1","SMURF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13873","full_name":"Bone morphogenetic protein receptor type-2","aliases":["Bone morphogenetic protein receptor type II","BMP type II receptor","BMPR-II"],"length_aa":1038,"mass_kda":115.2,"function":"On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Can also mediate signaling through the activation of the p38MAPK cascade (PubMed:12045205). Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6. Promotes signaling also by binding to activin A/INHBA (PubMed:24018044)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q13873/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BMPR2","classification":"Not Classified","n_dependent_lines":14,"n_total_lines":1208,"dependency_fraction":0.011589403973509934},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BMPR2","total_profiled":1310},"omim":[{"mim_id":"620997","title":"SEMAPHORIN 3G; SEMA3G","url":"https://www.omim.org/entry/620997"},{"mim_id":"620777","title":"PULMONARY HYPERTENSION, PRIMARY, 6; PPH6","url":"https://www.omim.org/entry/620777"},{"mim_id":"619560","title":"MICRO RNA 135B; MIR135B","url":"https://www.omim.org/entry/619560"},{"mim_id":"614823","title":"AORTIC VALVE DISEASE 2; AOVD2","url":"https://www.omim.org/entry/614823"},{"mim_id":"613127","title":"CHORDIN-LIKE 2; CHRDL2","url":"https://www.omim.org/entry/613127"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BMPR2"},"hgnc":{"alias_symbol":["BRK-3","T-ALK","BMPR3","BMPR-II"],"prev_symbol":["PPH1"]},"alphafold":{"accession":"Q13873","domains":[{"cath_id":"2.10.60.10","chopping":"33-130","consensus_level":"high","plddt":76.8197,"start":33,"end":130},{"cath_id":"3.30.200.20","chopping":"200-282","consensus_level":"medium","plddt":92.7072,"start":200,"end":282},{"cath_id":"1.10.510.10","chopping":"285-512","consensus_level":"high","plddt":90.2611,"start":285,"end":512}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13873","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13873-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13873-F1-predicted_aligned_error_v6.png","plddt_mean":57.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BMPR2","jax_strain_url":"https://www.jax.org/strain/search?query=BMPR2"},"sequence":{"accession":"Q13873","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13873.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13873/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13873"}},"corpus_meta":[{"pmid":"10903931","id":"PMC_10903931","title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.","date":"2000","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10903931","citation_count":861,"is_preprint":false},{"pmid":"11015450","id":"PMC_11015450","title":"Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.","date":"2000","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11015450","citation_count":528,"is_preprint":false},{"pmid":"26076038","id":"PMC_26076038","title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26076038","citation_count":410,"is_preprint":false},{"pmid":"23867624","id":"PMC_23867624","title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23867624","citation_count":359,"is_preprint":false},{"pmid":"26795434","id":"PMC_26795434","title":"BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.","date":"2016","source":"The Lancet. Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26795434","citation_count":343,"is_preprint":false},{"pmid":"16429395","id":"PMC_16429395","title":"Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16429395","citation_count":301,"is_preprint":false},{"pmid":"10880444","id":"PMC_10880444","title":"BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10880444","citation_count":212,"is_preprint":false},{"pmid":"25863249","id":"PMC_25863249","title":"BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.","date":"2015","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25863249","citation_count":197,"is_preprint":false},{"pmid":"30430573","id":"PMC_30430573","title":"Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30430573","citation_count":157,"is_preprint":false},{"pmid":"21737550","id":"PMC_21737550","title":"Targeted gene delivery of BMPR2 attenuates pulmonary hypertension.","date":"2011","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/21737550","citation_count":153,"is_preprint":false},{"pmid":"15286002","id":"PMC_15286002","title":"BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia.","date":"2004","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15286002","citation_count":151,"is_preprint":false},{"pmid":"16429403","id":"PMC_16429403","title":"BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16429403","citation_count":151,"is_preprint":false},{"pmid":"12358323","id":"PMC_12358323","title":"BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.","date":"2002","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/12358323","citation_count":145,"is_preprint":false},{"pmid":"17065373","id":"PMC_17065373","title":"Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?","date":"2006","source":"Proceedings of the American Thoracic Society","url":"https://pubmed.ncbi.nlm.nih.gov/17065373","citation_count":141,"is_preprint":false},{"pmid":"24446489","id":"PMC_24446489","title":"Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24446489","citation_count":130,"is_preprint":false},{"pmid":"9193425","id":"PMC_9193425","title":"Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.","date":"1997","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/9193425","citation_count":118,"is_preprint":false},{"pmid":"16717148","id":"PMC_16717148","title":"Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.","date":"2006","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/16717148","citation_count":112,"is_preprint":false},{"pmid":"23676498","id":"PMC_23676498","title":"BMPR2 is required for postimplantation uterine function and pregnancy maintenance.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23676498","citation_count":105,"is_preprint":false},{"pmid":"14583445","id":"PMC_14583445","title":"Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14583445","citation_count":103,"is_preprint":false},{"pmid":"30200294","id":"PMC_30200294","title":"TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30200294","citation_count":101,"is_preprint":false},{"pmid":"22348410","id":"PMC_22348410","title":"BMPR2 expression is suppressed by signaling through the estrogen receptor.","date":"2012","source":"Biology of sex differences","url":"https://pubmed.ncbi.nlm.nih.gov/22348410","citation_count":101,"is_preprint":false},{"pmid":"30582451","id":"PMC_30582451","title":"Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/30582451","citation_count":101,"is_preprint":false},{"pmid":"30586714","id":"PMC_30586714","title":"Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.","date":"2019","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/30586714","citation_count":100,"is_preprint":false},{"pmid":"31826007","id":"PMC_31826007","title":"BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/31826007","citation_count":95,"is_preprint":false},{"pmid":"36603064","id":"PMC_36603064","title":"BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36603064","citation_count":94,"is_preprint":false},{"pmid":"33497359","id":"PMC_33497359","title":"17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33497359","citation_count":90,"is_preprint":false},{"pmid":"23669347","id":"PMC_23669347","title":"The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23669347","citation_count":88,"is_preprint":false},{"pmid":"22180660","id":"PMC_22180660","title":"Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.","date":"2011","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22180660","citation_count":84,"is_preprint":false},{"pmid":"15775752","id":"PMC_15775752","title":"Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension.","date":"2005","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15775752","citation_count":83,"is_preprint":false},{"pmid":"33380512","id":"PMC_33380512","title":"Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.","date":"2021","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/33380512","citation_count":83,"is_preprint":false},{"pmid":"27811071","id":"PMC_27811071","title":"BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.","date":"2016","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/27811071","citation_count":78,"is_preprint":false},{"pmid":"15188402","id":"PMC_15188402","title":"Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry.","date":"2004","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/15188402","citation_count":77,"is_preprint":false},{"pmid":"10859286","id":"PMC_10859286","title":"QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish.","date":"2000","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10859286","citation_count":77,"is_preprint":false},{"pmid":"22388934","id":"PMC_22388934","title":"BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAH.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22388934","citation_count":71,"is_preprint":false},{"pmid":"30149506","id":"PMC_30149506","title":"Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30149506","citation_count":66,"is_preprint":false},{"pmid":"10712363","id":"PMC_10712363","title":"Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.","date":"2000","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10712363","citation_count":65,"is_preprint":false},{"pmid":"21801371","id":"PMC_21801371","title":"Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.","date":"2011","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/21801371","citation_count":55,"is_preprint":false},{"pmid":"21696628","id":"PMC_21696628","title":"Physiologic and molecular consequences of endothelial Bmpr2 mutation.","date":"2011","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/21696628","citation_count":53,"is_preprint":false},{"pmid":"34256859","id":"PMC_34256859","title":"Exosomal miR-100-5p inhibits osteogenesis of hBMSCs and angiogenesis of HUVECs by suppressing the BMPR2/Smad1/5/9 signalling pathway.","date":"2021","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34256859","citation_count":52,"is_preprint":false},{"pmid":"22632830","id":"PMC_22632830","title":"Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers.","date":"2012","source":"The American journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/22632830","citation_count":50,"is_preprint":false},{"pmid":"16024566","id":"PMC_16024566","title":"Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension.","date":"2005","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16024566","citation_count":47,"is_preprint":false},{"pmid":"29739878","id":"PMC_29739878","title":"BMPR2 inhibits activin and BMP signaling via wild-type ALK2.","date":"2018","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/29739878","citation_count":46,"is_preprint":false},{"pmid":"33080042","id":"PMC_33080042","title":"Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33080042","citation_count":46,"is_preprint":false},{"pmid":"30610955","id":"PMC_30610955","title":"HMGB1/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling.","date":"2019","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30610955","citation_count":45,"is_preprint":false},{"pmid":"36744494","id":"PMC_36744494","title":"Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36744494","citation_count":44,"is_preprint":false},{"pmid":"11298281","id":"PMC_11298281","title":"Pph1 from Myxococcus xanthus is a protein phosphatase involved in vegetative growth and development.","date":"2001","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11298281","citation_count":44,"is_preprint":false},{"pmid":"25663702","id":"PMC_25663702","title":"Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25663702","citation_count":43,"is_preprint":false},{"pmid":"19321386","id":"PMC_19321386","title":"TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases.","date":"2009","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19321386","citation_count":42,"is_preprint":false},{"pmid":"26589479","id":"PMC_26589479","title":"Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.","date":"2015","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26589479","citation_count":42,"is_preprint":false},{"pmid":"36917778","id":"PMC_36917778","title":"Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling.","date":"2023","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36917778","citation_count":40,"is_preprint":false},{"pmid":"22034596","id":"PMC_22034596","title":"Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.","date":"2011","source":"Pulmonary circulation","url":"https://pubmed.ncbi.nlm.nih.gov/22034596","citation_count":40,"is_preprint":false},{"pmid":"26809239","id":"PMC_26809239","title":"BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.","date":"2016","source":"Respirology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/26809239","citation_count":39,"is_preprint":false},{"pmid":"33399862","id":"PMC_33399862","title":"Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.","date":"2021","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33399862","citation_count":39,"is_preprint":false},{"pmid":"25501832","id":"PMC_25501832","title":"BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25501832","citation_count":38,"is_preprint":false},{"pmid":"18321866","id":"PMC_18321866","title":"Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18321866","citation_count":37,"is_preprint":false},{"pmid":"25205038","id":"PMC_25205038","title":"BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25205038","citation_count":35,"is_preprint":false},{"pmid":"24936649","id":"PMC_24936649","title":"Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24936649","citation_count":35,"is_preprint":false},{"pmid":"26689975","id":"PMC_26689975","title":"BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.","date":"2015","source":"Respirology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/26689975","citation_count":34,"is_preprint":false},{"pmid":"19782107","id":"PMC_19782107","title":"GDF5 and BMP2 inhibit apoptosis via activation of BMPR2 and subsequent stabilization of XIAP.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19782107","citation_count":34,"is_preprint":false},{"pmid":"17641158","id":"PMC_17641158","title":"Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.","date":"2007","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17641158","citation_count":33,"is_preprint":false},{"pmid":"34818449","id":"PMC_34818449","title":"The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34818449","citation_count":32,"is_preprint":false},{"pmid":"32692930","id":"PMC_32692930","title":"TWIST1 Drives Smooth Muscle Cell Proliferation in Pulmonary Hypertension via Loss of GATA-6 and BMPR2.","date":"2020","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32692930","citation_count":32,"is_preprint":false},{"pmid":"34023242","id":"PMC_34023242","title":"Significance of BMPR2 mutations in pulmonary arterial hypertension.","date":"2021","source":"Respiratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34023242","citation_count":31,"is_preprint":false},{"pmid":"29208670","id":"PMC_29208670","title":"Inhibition of ID1-BMPR2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29208670","citation_count":31,"is_preprint":false},{"pmid":"34400635","id":"PMC_34400635","title":"Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34400635","citation_count":30,"is_preprint":false},{"pmid":"33374819","id":"PMC_33374819","title":"Novel Advances in Modifying BMPR2 Signaling in PAH.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33374819","citation_count":29,"is_preprint":false},{"pmid":"28977600","id":"PMC_28977600","title":"ALK2/ALK3-BMPR2/ACVR2A Mediate BMP2-Induced Downregulation of Pentraxin 3 Expression in Human Granulosa-Lutein Cells.","date":"2017","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28977600","citation_count":29,"is_preprint":false},{"pmid":"17203235","id":"PMC_17203235","title":"Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.","date":"2007","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17203235","citation_count":28,"is_preprint":false},{"pmid":"36719862","id":"PMC_36719862","title":"Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36719862","citation_count":26,"is_preprint":false},{"pmid":"29481792","id":"PMC_29481792","title":"Fasudil inhibits neutrophil-endothelial cell interactions by regulating the expressions of GRP78 and BMPR2.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29481792","citation_count":26,"is_preprint":false},{"pmid":"28938584","id":"PMC_28938584","title":"BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28938584","citation_count":25,"is_preprint":false},{"pmid":"36344664","id":"PMC_36344664","title":"An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36344664","citation_count":24,"is_preprint":false},{"pmid":"31889906","id":"PMC_31889906","title":"miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31889906","citation_count":24,"is_preprint":false},{"pmid":"34502015","id":"PMC_34502015","title":"Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502015","citation_count":23,"is_preprint":false},{"pmid":"23142694","id":"PMC_23142694","title":"ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells.","date":"2012","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/23142694","citation_count":23,"is_preprint":false},{"pmid":"36064455","id":"PMC_36064455","title":"Hsa_circ_0001485 promoted osteogenic differentiation by targeting BMPR2 to activate the TGFβ-BMP pathway.","date":"2022","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36064455","citation_count":23,"is_preprint":false},{"pmid":"23579436","id":"PMC_23579436","title":"Alu-mediated nonallelic homologous and nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension.","date":"2013","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23579436","citation_count":23,"is_preprint":false},{"pmid":"32028950","id":"PMC_32028950","title":"Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: a meta-analysis.","date":"2020","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/32028950","citation_count":22,"is_preprint":false},{"pmid":"26167679","id":"PMC_26167679","title":"Mutation in BMPR2 Promoter: A 'Second Hit' for Manifestation of Pulmonary Arterial Hypertension?","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26167679","citation_count":22,"is_preprint":false},{"pmid":"10964520","id":"PMC_10964520","title":"A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. The International PPH Consortium.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10964520","citation_count":21,"is_preprint":false},{"pmid":"32350411","id":"PMC_32350411","title":"BMPR2 promotes fatty acid oxidation and protects white adipocytes from cell death in mice.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32350411","citation_count":21,"is_preprint":false},{"pmid":"31850803","id":"PMC_31850803","title":"BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes.","date":"2019","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31850803","citation_count":21,"is_preprint":false},{"pmid":"14516151","id":"PMC_14516151","title":"Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.","date":"2003","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/14516151","citation_count":21,"is_preprint":false},{"pmid":"29142464","id":"PMC_29142464","title":"BMPR2 and HIF1-α overexpression in resected osteosarcoma correlates with distant metastasis and patient survival.","date":"2017","source":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","url":"https://pubmed.ncbi.nlm.nih.gov/29142464","citation_count":21,"is_preprint":false},{"pmid":"30218748","id":"PMC_30218748","title":"5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30218748","citation_count":20,"is_preprint":false},{"pmid":"34819148","id":"PMC_34819148","title":"The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis.","date":"2021","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34819148","citation_count":20,"is_preprint":false},{"pmid":"26535780","id":"PMC_26535780","title":"Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.","date":"2015","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26535780","citation_count":20,"is_preprint":false},{"pmid":"30977250","id":"PMC_30977250","title":"BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo.","date":"2019","source":"Respirology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/30977250","citation_count":20,"is_preprint":false},{"pmid":"20562228","id":"PMC_20562228","title":"BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.","date":"2010","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20562228","citation_count":20,"is_preprint":false},{"pmid":"33757126","id":"PMC_33757126","title":"SPARC-related modular calcium binding 1 regulates aortic valve calcification by disrupting BMPR-II/p-p38 signalling.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33757126","citation_count":19,"is_preprint":false},{"pmid":"39142248","id":"PMC_39142248","title":"Emerging role of BMPs/BMPR2 signaling pathway in treatment for pulmonary fibrosis.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/39142248","citation_count":19,"is_preprint":false},{"pmid":"24794464","id":"PMC_24794464","title":"Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.","date":"2014","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/24794464","citation_count":19,"is_preprint":false},{"pmid":"21538804","id":"PMC_21538804","title":"BMPR-II is dispensable for formation of the limb skeleton.","date":"2011","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/21538804","citation_count":19,"is_preprint":false},{"pmid":"34061599","id":"PMC_34061599","title":"A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells.","date":"2021","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/34061599","citation_count":19,"is_preprint":false},{"pmid":"28391780","id":"PMC_28391780","title":"Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.","date":"2017","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/28391780","citation_count":19,"is_preprint":false},{"pmid":"33500333","id":"PMC_33500333","title":"PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation.","date":"2021","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/33500333","citation_count":19,"is_preprint":false},{"pmid":"28507310","id":"PMC_28507310","title":"Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28507310","citation_count":18,"is_preprint":false},{"pmid":"34161760","id":"PMC_34161760","title":"BMPR-2 gates activity-dependent stabilization of primary dendrites during mitral cell remodeling.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34161760","citation_count":17,"is_preprint":false},{"pmid":"31578224","id":"PMC_31578224","title":"A PINCH-1-Smurf1 signaling axis mediates mechano-regulation of BMPR2 and stem cell differentiation.","date":"2019","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31578224","citation_count":17,"is_preprint":false},{"pmid":"21962132","id":"PMC_21962132","title":"Variation in BMPR1B, TGFRB1 and BMPR2 and control of dizygotic twinning.","date":"2011","source":"Twin research and human genetics : the official journal of the International Society for Twin Studies","url":"https://pubmed.ncbi.nlm.nih.gov/21962132","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53811,"output_tokens":7565,"usd":0.137454,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17023,"output_tokens":7326,"usd":0.134132,"stage2_stop_reason":"end_turn"},"total_usd":0.271586,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"BMP-2 binds BMPR-II via a low-affinity epitope assembled from determinants of a single monomer (epitope 2), distinct from the high-affinity BMPR-IA binding epitope 1. Mutations in epitope 2 produce BMP-2 antagonists that partially or completely inhibit BMP-2 activity, defining the receptor recognition mechanism.\",\n      \"method\": \"BMP-2 mutant proteins analyzed for binding to receptor ectodomains; C2C12 cell bioassay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis and functional cell-based validation in a single rigorous study\",\n      \"pmids\": [\"10880444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tctex-1, a dynein light chain, interacts with the cytoplasmic domain of BMPR-II and is phosphorylated by BMPR-II. This interaction is isoform-specific (requiring the long cytoplasmic tail encoded partly by exon 12) and is disrupted by PPH disease-causing mutations within exon 12. BMPR-II and Tctex-1 co-localize in pulmonary vascular endothelium and smooth muscle.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro phosphorylation assay, immunofluorescence co-localization\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (Y2H, Co-IP, in vitro kinase assay, co-localization) in single lab\",\n      \"pmids\": [\"14583445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"GST pull-down with BMPR-II cytoplasmic domain constructs identified 33 interacting proteins including PKCβ and CtBP (confirmed by immunodetection), and showed that the C-terminal tail of BMPR-II provides distinct binding sites for regulatory proteins linking BMP signaling to MAP kinase pathway, apoptosis, transcription, PKCβ, and PKA.\",\n      \"method\": \"GST pull-down assay, 2D gel electrophoresis, MALDI-TOF-MS, immunodetection confirmation\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry interactome with two confirmed interactions by immunodetection, single lab\",\n      \"pmids\": [\"15188402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PAH-causing BMPR2 nonsense and frameshift mutations trigger nonsense-mediated decay (NMD), establishing haploinsufficiency as the predominant molecular mechanism. Missense mutations cause heterogeneous functional defects including impaired type I receptor phosphorylation and altered receptor complex stoichiometry. The intracellular domain of BMPR-II is both necessary and sufficient for receptor complex interaction.\",\n      \"method\": \"Enzymatic and fluorescence activity-based assays, splicing analysis, NMD inhibition, cell-based BMPR-II activity assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal functional methods establishing NMD, receptor stoichiometry, and domain sufficiency; consistent with independent studies\",\n      \"pmids\": [\"18321866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GDF5 and BMP2 prevent apoptosis in mouse embryonic fibroblasts (but not smooth muscle cells) via BMPR2. The mechanism involves BMPR2 stimulating the interaction with XIAP, reducing XIAP ubiquitination and increasing XIAP protein stability, which then inactivates activated caspases. This anti-apoptotic effect does not depend on Smad or MAPK signaling.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, BMPR2 loss-of-function, caspase activity assay, cell viability assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and functional rescue experiments, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19782107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BMPR2 mutations in pulmonary microvascular endothelial cells activate the Rho GTPase Rac1, causing cytoskeletal defects. Exogenous recombinant ACE2 corrects Rac1 defects in vitro and reverses established PAH in vivo in Rosa26-Bmpr2R899X transgenic mice.\",\n      \"method\": \"Expression arrays, Rac1 activity assay, stable transfection of BMPR2 mutations, in vivo mouse model with rhACE2 treatment\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell lines and in vivo rescue, single lab\",\n      \"pmids\": [\"22180660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mutant BMPR-II expression in pulmonary arterial endothelial cells increases susceptibility to apoptosis and causes secretion of elevated TGF-β1 and FGF2, which stimulate pulmonary arterial smooth muscle cell proliferation. Neutralizing antibodies to TGF-β1 or inhibitors of ALK-5 or FGFR1 blocked this paracrine proliferative effect.\",\n      \"method\": \"Adenoviral overexpression of wild-type or kinase-deficient BMPR-II mutant in PAECs, conditioned media experiments, ELISA, TGF-β bioassay, neutralizing antibodies, small molecule inhibitors\",\n      \"journal\": \"Pulmonary circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional conditioned media and neutralization experiments, single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"22034596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BMPR-II deficiency promotes activation of SMAD-independent MAPK pathways via TGFβ-associated kinase 1 (TAK1), resulting in pro-proliferative and anti-apoptotic responses in pulmonary arterial smooth muscle cells. TAK1 interacts with BMPR-II and inhibits BMP-responsive reporter activity; this interaction is greatly reduced by PAH-causing BMPR2 mutations.\",\n      \"method\": \"Primary PASMCs from knock-in mice, TAK1-MAPK inhibition rescue experiments, reporter assay, co-immunoprecipitation, in vivo rat PAH models\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP, reporter assays, epistatic rescue, and in vivo validation across multiple models in single study\",\n      \"pmids\": [\"22388934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Estrogen receptor alpha directly binds to a conserved site in the BMPR2 promoter (demonstrated by gel-shift/EMSA assay), and increased estrogen receptor alpha expression correlates with decreased BMPR2 transcription. Exogenous estrogen decreases BMPR2 expression in proliferating cells.\",\n      \"method\": \"Quantitative RT-PCR, gel mobility shift assay (EMSA), luciferase reporter assay, estrogen receptor transfection in cell culture, in vivo mouse studies\",\n      \"journal\": \"Biology of sex differences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — EMSA, luciferase, and in vivo data; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22348410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FK506 (tacrolimus) activates BMPR2 signaling via a dual mechanism: as a calcineurin inhibitor and by releasing FKBP12 from type I receptors ALK1, ALK2, and ALK3, thereby activating downstream SMAD1/5 and MAPK signaling and ID1 gene regulation. Low-dose FK506 reversed dysfunctional BMPR2 signaling in PAH patient endothelial cells and reversed established PAH in multiple rodent models.\",\n      \"method\": \"High-throughput luciferase reporter screen, FKBP12 binding assay, SMAD1/5 and MAPK phosphorylation assays, in vivo rat PAH models, conditional Bmpr2 deletion mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic dissection with multiple orthogonal methods, multiple in vivo models, validated in patient-derived cells\",\n      \"pmids\": [\"23867624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chloroquine increases cell surface expression of BMPR-II protein by inhibiting lysosomal degradation, independent of transcription. Cell surface BMPR-II has rapid turnover that is blocked by chloroquine. This restores BMP9-induced BMPR-II signaling (Id1, miR21, miR27a expression) in endothelial cells from PAH patients with BMPR-II mutations.\",\n      \"method\": \"Protein synthesis inhibition, cell surface expression assay, siRNA knockdown, BMP9 signaling assays (Id1, miR21/27a), blood outgrowth endothelial cells from PAH patients\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in patient-derived cells, single lab\",\n      \"pmids\": [\"23669347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Uterine decidua-specific deletion of Bmpr2 in mice leads to midgestation decidualization defects, abnormal vascular development, trophoblast defects, and deficiency of uterine natural killer cells. Absence of BMPR2 signaling in the uterine decidua suppresses IL-15, VEGF, angiopoietin, and corin signaling, resulting in placental abruption and fetal demise.\",\n      \"method\": \"Conditional Bmpr2 knockout (uterine-specific Cre), histology, immunofluorescence, gene expression analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with specific molecular pathway and multi-pathway phenotypic readout\",\n      \"pmids\": [\"23676498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Reduced BMPR2 in pulmonary artery endothelial cells, upon TNF stimulation, leads to prolonged phospho-p38 MAPK activity, increased GADD34-PP1 phosphatase activity, dephosphorylation of eIF2α, and consequent derepression of GM-CSF mRNA translation by disrupting stress granule formation. This mechanism increases GM-CSF production, macrophage recruitment, and exacerbates PAH.\",\n      \"method\": \"siRNA knockdown, phospho-protein analysis, stress granule assays, GADD34-PP1 activity assay, GM-CSF ELISA, GM-CSF infusion and blockade in mouse models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic pathway dissected with multiple biochemical methods and validated in vivo; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"24446489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BMPR2 deficiency in pulmonary arterial endothelial cells impairs mitochondrial biogenesis regulators (p53, PGC1α, NRF2, TFAM), reduces mitochondrial membrane potential and ATP production, induces mitochondrial DNA deletion and apoptosis during reoxygenation. In normoxia, BMPR2 reduction increases glycolysis, induces mitochondrial fission, and promotes a pro-inflammatory state.\",\n      \"method\": \"EC-specific Bmpr2 deletion mouse model, siRNA knockdown in PAECs, mitochondrial function assays (membrane potential, ATP, mtDNA), gene expression analysis\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in vivo plus siRNA in vitro, multiple orthogonal mitochondrial function assays, recapitulated in patient PAECs\",\n      \"pmids\": [\"25863249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BMP9 is the preferred ligand for BMPR-II-mediated prevention of apoptosis and enhancement of monolayer integrity in pulmonary arterial endothelial cells, including those from PAH patients with BMPR2 mutations. Administration of BMP9 reversed established PAH in BMPR2 R899X knock-in mice and in monocrotaline and Sugen/hypoxia rat models.\",\n      \"method\": \"BMPR2 R899X knock-in mouse model generation, apoptosis assays, endothelial monolayer integrity assays, in vivo BMP9 administration in three PAH models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — functional in vitro assays, novel knock-in animal model, replicated across three in vivo PAH models\",\n      \"pmids\": [\"26076038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of BMPR2 in mouse skeletal progenitor cells selectively impairs activin signaling but has no effect on BMP signaling, resulting in an increased bone formation rate and high bone mass. BMPR2 availability mediates receptor-level competition between BMPs and activins for ACVR2A/ACVR2B.\",\n      \"method\": \"Conditional Bmpr2 knockout in skeletal progenitors (Bmpr2-cKO mice), bone mass measurement, BMP and activin signaling assays, activin sequestration experiments\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with specific signaling pathway discrimination and genetic rescue experiments\",\n      \"pmids\": [\"25663702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BMPR2 gene delivery increases Smad1/5/8 signaling and reduces Smad2/3 signaling (switching TGF-β-Smad2/3 to BMPR2-Smad1/5/8), and also increases PI3K signaling and decreases p38-MAPK phosphorylation in vivo. These changes are associated with amelioration of PAH in the monocrotaline rat model.\",\n      \"method\": \"Adenoviral BMPR2 gene delivery to human pulmonary endothelial cells and in vivo rat PAH model, Western blotting for Smad and non-Smad signaling\",\n      \"journal\": \"Respirology (Carlton, Vic.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both in vitro and in vivo signaling pathway analysis, single lab\",\n      \"pmids\": [\"26809239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BMPR2 knockdown in multiple myeloma cells potentiates activin A-, activin B-, BMP6-, BMP7-, and BMP9-induced SMAD1/5/8 signaling through wild-type ALK2. The proposed mechanism is that BMPR2 inhibits ALK2-mediated signaling by preventing ALK2 from oligomerizing with ACVR2A and ACVR2B, which are required for ALK2 activation by activins and several BMPs.\",\n      \"method\": \"siRNA knockdown of BMPR2, SMAD1/5/8 phosphorylation assays, cell death assays in myeloma and HepG2 cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional siRNA knockdown with signaling readouts across two cell types; proposed oligomerization mechanism not directly demonstrated by structural method\",\n      \"pmids\": [\"29739878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BMPR2 deficiency in endothelial cells does not abolish BMP-SMAD1/5 responses but instead promotes formation of mixed heteromeric receptor complexes (BMPR1/TGFβR1/TGFβR2), enabling enhanced TGFβ-SMAD2/3 and lateral TGFβ-SMAD1/5 signaling. Loss of BMPR2 also causes ectopic fibrillin-1 accumulation with active β1-integrin in ILK mechano-complexes at cell junctions, increasing integrin-dependent contractility and retrieval of active TGFβ from latent fibrillin-bound depots.\",\n      \"method\": \"BMPR2 siRNA knockdown, SMAD phosphorylation assays, co-immunoprecipitation of receptor complexes, fibrillin-1 immunofluorescence, integrin adhesion/spreading assays, actomyosin contractility assays, patient tissue analysis\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal mechanistic methods including Co-IP of receptor complexes, biochemical signaling, matrix biology, and patient tissue validation\",\n      \"pmids\": [\"31826007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In SMC-EC contact cocultures, BMPR2 in both cell types is required to produce collagen IV, which activates ILK. ILK directs phospho-JNK to the EC membrane, stabilizing presenilin1 and releasing Notch1 intracellular domain (N1ICD) to promote EC proliferation. N1ICD maintains EC proliferative capacity by increasing mitochondrial mass and inducing PFKFB3, which is required for citrate-dependent H3K27 acetylation at enhancer sites.\",\n      \"method\": \"Co-culture experiments, EC-SMC Bmpr2 double heterozygous mouse model, carotid injury model, ChIP-seq, FRET imaging, conditional Notch1 deletion mice\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple genetic models, ChIP-seq, functional rescue, and FRET imaging in a single comprehensive study\",\n      \"pmids\": [\"30582451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TWIST1-dependent degradation of GATA-6 in smooth muscle cells reduces BMPR2 expression; GATA-6 directly binds to the BMPR2 promoter and promotes its expression. SMC-specific TWIST1 deficiency or silencing restored GATA-6-dependent BMPR2 expression and attenuated PH development.\",\n      \"method\": \"SMC-specific TWIST1 knockout mice, TWIST1 silencing in rats, chromatin immunoprecipitation (ChIP), immunoprecipitation (mass spectrometry), Western blotting\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP demonstrated direct GATA-6 binding to BMPR2 promoter; multiple genetic models; single lab with orthogonal methods\",\n      \"pmids\": [\"32692930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BMPR2 knockout in adipocytes impairs TNFα-stimulated lipolysis by inhibiting perilipin phosphorylation, leading to failure of fatty acid oxidation and oxidative phosphorylation, and consequent mitochondria-mediated apoptosis and pyroptosis with elevated inflammation.\",\n      \"method\": \"Conditional BMPR2 knockout in adipocytes, lipolysis assays, perilipin phosphorylation assay, fatty acid oxidation assay, apoptosis/pyroptosis assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific mechanistic readouts, single lab\",\n      \"pmids\": [\"32350411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A PINCH-1–Smurf1–BMPR2 signaling axis links extracellular matrix stiffness to mesenchymal stem cell osteogenic differentiation. PINCH-1 interacts with Smurf1, preventing Smurf1 from ubiquitinating and degrading BMPR2. ECM stiffening increases PINCH-1 levels, thereby protecting BMPR2 from degradation and augmenting BMP signaling. Depletion of either Smurf1 or BMPR2 blocks PINCH-1-induced osteogenic differentiation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, PINCH-1/Smurf1/BMPR2 knockdown and overexpression, soft/stiff ECM culture, osteogenic differentiation assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP, ubiquitination assay, epistatic rescue across multiple perturbations, and ECM stiffness experiments in single study\",\n      \"pmids\": [\"31578224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The kinase domain of the type I receptor ALK2 and the type II receptor BMPR2 form a heterodimeric complex via their C-terminal lobes. This heterodimer serves as the scaffold for assembly of active tetrameric receptor complexes enabling phosphorylation of the GS domain and activation of SMADs. PAH-causing mutations in BMPR2 target this kinase domain heterodimer interface.\",\n      \"method\": \"Hydrogen deuterium exchange mass spectrometry (HDX-MS), small angle X-ray scattering (SAXS), molecular dynamics (MD) simulations, SMAD signaling assays with PAH-associated mutants\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural study (HDX-MS, SAXS, MD) combined with functional signaling validation and disease mutation analysis\",\n      \"pmids\": [\"34400635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BMPR2 signaling through SMAD4/SMAD6 maintains high YY1 levels in latently HCMV-infected undifferentiated myeloid cells. BMPR2-activated SMAD4/6 inhibits TGFβ receptor signaling, preventing induction of hsa-miR-29a that would degrade YY1. Pharmacological targeting of BMPR2 in progenitor cells results in YY1 degradation and loss of HCMV latency.\",\n      \"method\": \"iPSC model of HCMV latency, patient-derived myeloid progenitors, BMPR2 pharmacological inhibition, SMAD4/6 pathway analysis, miR-29a measurement, YY1 protein assays, T cell killing assays\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pharmacological and pathway assays in patient-derived cells and iPSC model; single lab\",\n      \"pmids\": [\"34061599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BMPR-2 in developing mitral cell dendrites inhibits LIMK activity in the absence of ligands, permitting dendrite destabilization. Ligand-bound BMPR-2 releases LIMK inhibition to stabilize dendrites. LIMK activated by NMDARs via Rac1 facilitates selective dendrite stabilization through F-actin formation.\",\n      \"method\": \"CRISPR-Cas9-based knockout screening, in utero electroporation, rescue experiments with Bmpr2 re-expression, BMP antagonist/agonist overexpression, Rac1 genetic experiments, FRET imaging of LIMK activity\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR KO with rescue, FRET imaging, and genetic epistasis across multiple neuronal experiments in single study\",\n      \"pmids\": [\"34161760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMOC1 binds directly to BMPR-II (via amino acids 372–383 of its EF-hand calcium-binding domain, shown by co-immunoprecipitation) and inhibits BMP2-induced phosphorylation of p38 (p-p38). Under high calcium conditions, SMOC1 loses its ability to bind BMPR-II, promoting p-p38 and cell apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping with truncation mutants, p38 phosphorylation assays, p38 inhibitor experiments, in vitro and in vivo calcification models\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and functional signaling rescue; single lab\",\n      \"pmids\": [\"33757126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of BMPR2 in smooth muscle cells causes upregulation of pERK1/2-pP38-pSMAD2/3, elevation of β-arrestin2 (ARRB2), pAKT inactivation of GSK3-beta, CTNNB1 nuclear translocation, and reduction in RHOA and RAC1, resulting in hypocontractile and hyperproliferative PASMC phenotype. Decreasing ARRB2 in BMPR2-deficient SMC restores normal signaling and reverses the aberrant phenotype.\",\n      \"method\": \"SMC-specific Bmpr2 knockout mice, siRNA in human PASMC, PASMC from PAH patients with BMPR2 mutations, phosphoprotein analysis, ARRB2 knockdown rescue experiments, echocardiography and hemodynamic measurements\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (mouse KO, human siRNA, patient cells), epistatic rescue via ARRB2 knockdown, multiple orthogonal signaling readouts\",\n      \"pmids\": [\"36744494\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BMPR2 is a type II serine/threonine kinase receptor that forms heterotetrameric complexes with type I receptors (ALK1/2/3) via C-terminal lobe kinase domain dimerization to phosphorylate the GS domain and activate canonical SMAD1/5/8 signaling; it acts as a gatekeeper preventing TGFβ-SMAD2/3 and lateral signaling by competing for type I/II receptor complex formation, regulates non-canonical pathways including MAPK (via TAK1 and ERK/Raf), PI3K, and ARRB2/β-catenin; it phosphorylates dynein light chain Tctex-1, interacts with XIAP to suppress apoptosis, and its cytoplasmic tail recruits PKCβ, CtBP, and other regulatory proteins; its cell-surface abundance is controlled by lysosomal degradation (regulated by PINCH-1/Smurf1 ubiquitination and blocked by chloroquine), and its transcription is suppressed by direct estrogen receptor alpha binding to the BMPR2 promoter and promoted by GATA-6; haploinsufficiency resulting from loss-of-function mutations is the predominant molecular mechanism underlying pulmonary arterial hypertension.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BMPR2 is a type II receptor kinase that nucleates BMP signaling by forming a heterodimeric complex with type I receptor kinase domains (e.g. ALK2) through their C-terminal lobes, a scaffold required for GS-domain phosphorylation and activation of canonical SMAD1/5/8 signaling [#23]. Ligand recognition occurs through a distinct low-affinity epitope on BMP ligands separate from the type I receptor epitope [#0], and the intracellular domain is necessary and sufficient for receptor complex assembly [#3]. Beyond its canonical role, BMPR2 acts as a gatekeeper of receptor pairing: its loss does not abolish SMAD1/5 responses but instead drives formation of mixed BMPR1/TGFβR complexes that potentiate TGFβ-SMAD2/3 and lateral SMAD1/5 signaling [#18], and by sequestering shared type II receptors ACVR2A/ACVR2B it restrains activin- and BMP-driven ALK2 signaling [#15, #17]. The long cytoplasmic tail serves as a regulatory platform, binding and phosphorylating the dynein light chain Tctex-1 in an isoform-specific manner disrupted by disease mutations [#1] and recruiting additional partners including PKCβ and CtBP [#2]. BMPR2 restrains non-canonical signaling — TAK1-dependent MAPK, p38, ERK, PI3K, and ARRB2/β-catenin axes — such that its deficiency produces pro-proliferative, hypocontractile, and pro-inflammatory states in vascular cells [#7, #16, #27], and it suppresses apoptosis through stabilization of XIAP independently of SMAD/MAPK [#4]. Cell-surface abundance is set post-translationally by lysosomal turnover that is opposed by a PINCH-1–Smurf1 ubiquitination axis [#10, #22], while transcription is repressed by estrogen receptor alpha binding to the BMPR2 promoter [#8] and promoted by GATA-6, whose TWIST1-driven degradation lowers BMPR2 [#20]. Loss-of-function BMPR2 mutations cause haploinsufficiency, predominantly via nonsense-mediated decay, and are the major molecular cause of pulmonary arterial hypertension [#3]; BMPR2 deficiency in pulmonary vascular cells drives endothelial apoptosis, paracrine smooth-muscle proliferation, mitochondrial dysfunction, and inflammatory amplification underlying the disease [#6, #13, #12]. BMPR2 additionally functions across diverse tissues, controlling uterine decidualization and placentation [#11], skeletal bone mass via activin signaling competition [#15], adipocyte lipolysis [#21], and dendrite stabilization in neurons through ligand-gated control of LIMK [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established how BMP ligands are recognized by BMPR-II versus the type I receptor, defining the molecular basis of receptor engagement.\",\n      \"evidence\": \"BMP-2 mutagenesis and binding to receptor ectodomains with C2C12 bioassay\",\n      \"pmids\": [\"10880444\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the assembled tetrameric receptor architecture\", \"Affinity contributions of full-length membrane receptors not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the long cytoplasmic tail as a functional signaling platform by showing isoform-specific binding and phosphorylation of the dynein light chain Tctex-1, linking BMPR-II to disease mutations in exon 12.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, in vitro kinase assay, immunofluorescence\",\n      \"pmids\": [\"14583445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Tctex-1 phosphorylation undefined\", \"Role in dynein-dependent transport not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapped the cytoplasmic tail interactome, linking BMPR-II to MAPK, apoptosis, transcription, and kinase pathways through distinct binding sites.\",\n      \"evidence\": \"GST pull-down, 2D gel, MALDI-TOF-MS, immunodetection\",\n      \"pmids\": [\"15188402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only PKCβ and CtBP confirmed; remaining 31 interactions unvalidated\", \"No functional assignment to individual interactions\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the molecular mechanism of PAH-causing mutations, establishing nonsense-mediated decay-driven haploinsufficiency and demonstrating the intracellular domain is necessary and sufficient for complex formation.\",\n      \"evidence\": \"Splicing/NMD analysis and cell-based BMPR-II activity assays\",\n      \"pmids\": [\"18321866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterogeneous missense defects not mechanistically unified\", \"Downstream pathway consequences of haploinsufficiency not addressed here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a SMAD/MAPK-independent anti-apoptotic function of BMPR2 via XIAP stabilization, expanding its role beyond transcriptional signaling.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, caspase and viability assays in MEFs\",\n      \"pmids\": [\"19782107\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type specificity (absent in SMCs) unexplained\", \"Mechanism of XIAP de-ubiquitination not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected BMPR2 mutation to vascular cytoskeletal defects via Rac1 activation and identified ACE2 as a corrective intervention in vivo.\",\n      \"evidence\": \"Rac1 activity assays, mutant transfection, rhACE2 in transgenic mice\",\n      \"pmids\": [\"22180660\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking BMPR2 to Rac1 not defined\", \"How ACE2 corrects Rac1 unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed mutant BMPR-II drives paracrine smooth-muscle proliferation through endothelial secretion of TGF-β1 and FGF2, a non-cell-autonomous disease mechanism.\",\n      \"evidence\": \"Adenoviral mutant expression, conditioned media, neutralizing antibodies and inhibitors\",\n      \"pmids\": [\"22034596\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream control of cytokine secretion not defined\", \"In vivo relevance of paracrine loop not tested here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified TAK1 as the mediator coupling BMPR-II deficiency to SMAD-independent MAPK-driven proliferation and survival, with the interaction lost in disease mutants.\",\n      \"evidence\": \"Primary PASMCs, Co-IP, reporter assays, inhibitor rescue, in vivo rat models\",\n      \"pmids\": [\"22388934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TAK1-BMPR-II interaction unknown\", \"Relative contribution versus other non-canonical pathways unquantified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established direct transcriptional repression of BMPR2 by estrogen receptor alpha, providing a basis for sex differences in BMPR2 expression.\",\n      \"evidence\": \"EMSA, luciferase reporter, ERα transfection, in vivo mouse studies\",\n      \"pmids\": [\"22348410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo physiological impact on disease not fully resolved\", \"Interaction with other promoter regulators unaddressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated pharmacological activation of BMPR2 signaling: FK506 via FKBP12 release and chloroquine via blocked lysosomal degradation, restoring signaling in patient cells.\",\n      \"evidence\": \"Reporter screen, FKBP12 binding, SMAD/MAPK phospho-assays, in vivo models, patient endothelial cells\",\n      \"pmids\": [\"23867624\", \"23669347\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the lysosomal targeting/turnover machinery incompletely defined\", \"Off-target/calcineurin-independent contributions of FK506 not separated in all contexts\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed an essential developmental role for BMPR2 in uterine decidualization and placentation through control of IL-15, VEGF, angiopoietin, and corin signaling.\",\n      \"evidence\": \"Uterine-specific conditional knockout, histology, gene expression\",\n      \"pmids\": [\"23676498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect regulation of each downstream factor unresolved\", \"Relevant cell type within decidua not fully defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Dissected an inflammatory amplification mechanism whereby reduced BMPR2 prolongs p38 activity and derepresses GM-CSF translation via GADD34-PP1 and stress-granule disruption.\",\n      \"evidence\": \"siRNA, phospho-protein and stress-granule assays, GM-CSF ELISA, mouse infusion/blockade\",\n      \"pmids\": [\"24446489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BMPR2 loss sustains p38 activity mechanistically unclear\", \"Generalizability beyond TNF stimulation untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established BMPR2 as a regulator of endothelial mitochondrial biogenesis, metabolism, and survival, linking its loss to glycolytic shift and apoptosis.\",\n      \"evidence\": \"EC-specific Bmpr2 deletion, siRNA, mitochondrial function assays, patient PAECs\",\n      \"pmids\": [\"25863249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling route from receptor to biogenesis regulators not mapped\", \"Reversibility of metabolic defects untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified BMP9 as the preferred protective ligand for endothelial integrity and showed BMP9 reverses established PAH across multiple models, defining a therapeutic ligand axis.\",\n      \"evidence\": \"R899X knock-in mice, apoptosis/monolayer assays, BMP9 in three PAH models\",\n      \"pmids\": [\"26076038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor complex specificity for BMP9 protection not fully resolved\", \"Durability of BMP9 effect untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed BMPR2 sets ligand competition at the receptor level, sequestering type II receptors so that its loss selectively augments activin signaling and bone mass.\",\n      \"evidence\": \"Skeletal progenitor conditional knockout, BMP/activin signaling and sequestration assays\",\n      \"pmids\": [\"25663702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometric basis of receptor competition not structurally defined\", \"Tissue-specific differences in competition outcome unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Generalized the gatekeeper model, showing BMPR2 loss potentiates ALK2 signaling by permitting ACVR2A/ACVR2B oligomerization with ALK2 in myeloma cells.\",\n      \"evidence\": \"siRNA knockdown, SMAD1/5/8 phospho-assays in myeloma and HepG2 cells\",\n      \"pmids\": [\"29739878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proposed oligomerization mechanism not directly shown by structural method\", \"Single knockdown approach without reciprocal validation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated that BMPR2 loss reroutes receptor pairing into mixed BMPR1/TGFβR complexes and triggers fibrillin-1/integrin mechano-complex changes that retrieve active TGFβ, mechanistically unifying canonical and matrix-driven dysregulation.\",\n      \"evidence\": \"siRNA, receptor complex Co-IP, fibrillin-1 IF, integrin/contractility assays, patient tissue\",\n      \"pmids\": [\"31826007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of events between receptor mispairing and matrix changes unresolved\", \"Quantitative balance of lateral versus canonical signaling unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked BMPR2 in EC-SMC contact to a collagen IV–ILK–JNK–Notch1 axis that maintains EC proliferative metabolism via PFKFB3 and histone acetylation.\",\n      \"evidence\": \"Co-culture, double-heterozygous mouse model, ChIP-seq, FRET, Notch1 deletion\",\n      \"pmids\": [\"30582451\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct receptor-level trigger for collagen IV production not defined\", \"Whether this axis operates in human disease tissue untested here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established the PINCH-1–Smurf1 axis controlling BMPR2 protein stability and linked ECM stiffness to BMP signaling output in stem cell differentiation.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, epistatic knockdown/overexpression, ECM stiffness culture\",\n      \"pmids\": [\"31578224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ECM stiffness raises PINCH-1 levels not defined\", \"Relevance to vascular BMPR2 turnover not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a TWIST1–GATA-6 transcriptional circuit controlling BMPR2 expression, identifying GATA-6 as a direct positive promoter regulator counteracted by TWIST1-driven degradation.\",\n      \"evidence\": \"SMC-specific TWIST1 knockout, ChIP, IP-MS, in vivo PH models\",\n      \"pmids\": [\"32692930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals controlling TWIST1 in SMCs unclear\", \"Interaction with ERα-mediated repression not integrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended BMPR2 function to adipocyte metabolism, showing it is required for TNFα-stimulated lipolysis, fatty acid oxidation, and protection from mitochondria-mediated cell death.\",\n      \"evidence\": \"Adipocyte conditional knockout, lipolysis, perilipin phosphorylation, FAO assays\",\n      \"pmids\": [\"32350411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct signaling route from BMPR2 to perilipin phosphorylation unknown\", \"Systemic metabolic consequences not detailed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the structural basis of receptor activation, showing the ALK2-BMPR2 kinase domains form a C-terminal-lobe heterodimer that scaffolds the active tetramer and is targeted by PAH mutations.\",\n      \"evidence\": \"HDX-MS, SAXS, MD simulations, SMAD signaling with disease mutants\",\n      \"pmids\": [\"34400635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution crystal/cryo-EM structure of full tetramer not obtained\", \"Generality across all type I receptors not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Uncovered a BMPR2-SMAD4/6-YY1 axis maintaining HCMV latency in myeloid progenitors, identifying BMPR2 as a target for latency reversal.\",\n      \"evidence\": \"iPSC and patient myeloid latency models, BMPR2 inhibition, miR-29a/YY1 assays\",\n      \"pmids\": [\"34061599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect SMAD4/6 control of YY1 not fully separated\", \"Pharmacological specificity of BMPR2 inhibition uncertain\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated a ligand-gated function of BMPR-2 in neurons, controlling dendrite stabilization through inhibition or release of LIMK activity.\",\n      \"evidence\": \"CRISPR KO screen, in utero electroporation, rescue, FRET imaging, Rac1 epistasis\",\n      \"pmids\": [\"34161760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical mechanism of LIMK inhibition by apo-BMPR-2 undefined\", \"Whether disease mutations affect this neuronal function untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified SMOC1 as a calcium-sensitive direct BMPR-II binder that restrains p38 signaling and apoptosis, adding a ligand-independent modulator.\",\n      \"evidence\": \"Co-IP, domain mapping, p38 phospho-assays, calcification models\",\n      \"pmids\": [\"33757126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal validation of SMOC1-BMPR-II binding limited\", \"Physiological context beyond calcification unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the integrated non-canonical signaling derangement of BMPR2-deficient smooth muscle and identified ARRB2 as a tractable node whose reduction restores the contractile phenotype.\",\n      \"evidence\": \"SMC-specific knockout, human/patient PASMC siRNA, phosphoprotein analysis, ARRB2 rescue, hemodynamics\",\n      \"pmids\": [\"36744494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BMPR2 loss elevates ARRB2 mechanistically unknown\", \"Integration with TAK1/p38 pathways not unified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse cytoplasmic-tail partners, receptor-competition gatekeeping, and tissue-specific phenotypes are mechanistically integrated into a single quantitative model of BMPR2 signaling output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking canonical SMAD output to the many non-canonical and matrix-driven effects\", \"Tissue specificity of partner usage undefined\", \"Structural model of the full ligand-bound tetramer incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 3, 23]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 23, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [15, 17, 18]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 7, 23, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 6, 13]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 13, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 15, 25]}\n    ],\n    \"complexes\": [\n      \"BMP type I/II receptor heterotetramer (ALK2-BMPR2)\",\n      \"PINCH-1-Smurf1-BMPR2 axis\",\n      \"ILK mechano-complex (matrix-associated)\"\n    ],\n    \"partners\": [\n      \"ALK2\",\n      \"TAK1\",\n      \"XIAP\",\n      \"Tctex-1\",\n      \"PKCB\",\n      \"CtBP\",\n      \"SMOC1\",\n      \"Smurf1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}